

- References :**
1. Médecine personnalisée et cancer du sein : médecine anticipatoire, évaluation pronostique et ciblage thérapeutique Anthony Goncalves, Jessica Moretta, Francois Eisinger, Francois Bertucci.
 2. Coates AS, Winer EP, Goldhirsch A, et al (2005) Tailoring thérapies_ improving the management of early breast cancer ;St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26 :1533-46.
 - 3.EPU Pathologie Mammaire 2017 G. Mac Grogan, A. Vincent-Salomon, L. Arnould.
 - 3.Aleskandaramy et al Br Can Res TTT2011, 127 :591-599.
 - 4.Targeted approches for HER2 breast cancer therapy : New from nanomedecine ? World J Pharmacol. Dec 9, 2014 ; 3(4) : 72-85.
 - 5.Ihemelandu CU et al. Molecular breast cancer subtypes in premenopausal and post menopausal African American Women; J of surgical research; 143. 109-118 (2007).
 6. El hawary Amira et al; Molecular subtypes of breast cancer in Egyptian women clinicopathological features. PATHOLOGY-RESEARCH AND PRACTICE 2012. 382-386.
 7. Cheang et al; Ki67 index,Her2 status and prognosis of patients with luminal B breast cancer. vol101 issue 10; May 20 2009
 - 8.FITZGIBBONS PL et al. Prognostic factors in breast cancer. College of AmericanPathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124: 966-78.